• For the latest updates on our ongoing response to COVID-19, please click here.

    Pipeline

    The impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next. We discover, identify and evaluate investigational compounds that show potential to advance the treatment of life-threatening diseases.

    The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

    Pipeline

    Viral?Diseases

    • Remdesivir

      COVID-19

      Phase 1
      Phase 2
      Phase 3
    • Biktarvy?(BIC/FTC/TAF)

      HIV treatment pediatric1

      Phase 1
      Phase 2
      Phase 3
    • Lenacapavir capsid inhibitor (GS-6207)

      HIV HTE2?

      Phase 1
      Phase 2
      Phase 3
    • Lenacapavir capsid inhibitor (GS-6207)

      HIV treatment na?ve

      Phase 1
      Phase 2
      Phase 3
    • Long acting treatment: 2 bNAbs (GS-5423, GS-2872)

      HIV cure3

      Phase 1
      Phase 2
      Phase 3
    • Vesatolimod TLR-7 agonist (GS-9620)

      HIV cure

      Phase 1
      Phase 2
      Phase 3
    • Elipovimab bNAb (GS-9722)

      HIV cure

      Phase 1
      Phase 2
      Phase 3
    • Unboosted protease inhibitor (GS-1156)

      HIV treatment

      Phase 1
      Phase 2
      Phase 3
    • Selgantolimod TLR-8 agonist (GS-9688)

      HBV cure

      Phase 1
      Phase 2
      Phase 3
    • PD-L1 inhibitor (GS-4224)

      HBV cure

      Phase 1
      Phase 2
      Phase 3

    1 Biktarvy HIV treatment pediatric label extension.

    2 Registrational for heavily treatment-experienced (HTE) patients.

    3 Phase 2 studies are academic collaborations.

    Inflammatory diseases

    • Filgotinib JAK-1 inhibitor (GS-6034)

      Rheumatoid arthritis

      Phase 1
      Phase 2
      Phase 3
    • Filgotinib JAK-1 inhibitor (GS-6034)

      Ulcerative colitis

      Phase 1
      Phase 2
      Phase 3
    • Filgotinib JAK-1 inhibitor (GS-6034)

      Crohn's disease

      Phase 1
      Phase 2
      Phase 3
    • Filgotinib JAK-1 inhibitor (GS-6034)

      Psoriatic arthritis

      Phase 1
      Phase 2
      Phase 3
    • Filgotinib JAK-1 inhibitor (GS-6034)

      Ankylosing spondylitis

      Phase 1
      Phase 2
      Phase 3
    • Filgotinib JAK-1 inhibitor (GS-6034)

      Uveitis

      Phase 1
      Phase 2
      Phase 3
    • TPL2 inhibitor (GS-4875)

      Ulcerative colitis

      Phase 1
      Phase 2
      Phase 3
    • GLPG-19721

      Osteoarthritis

      Phase 1
      Phase 2
      Phase 3
    • GLPG-05551

      Inflammatory diseases

      Phase 1
      Phase 2
      Phase 3
    • GLPG-33121

      Inflammatory diseases

      Phase 1
      Phase 2
      Phase 3
    • GLPG-39701

      Inflammatory diseases

      Phase 1
      Phase 2
      Phase 3
    • GLPG-36671

      Inflammatory diseases

      Phase 1
      Phase 2
      Phase 3
    • GLPG-31211

      Inflammatory diseases

      Phase 1
      Phase 2
      Phase 3

    1 Optionable partner program.

    Fibrotic Diseases

    • Cilofexor FXR agonist (GS-9674)

      PSC

      Phase 1
      Phase 2
      Phase 3
    • GLPG-16901

      Idiopathic Pulmonary Fibrosis

      Phase 1
      Phase 2
      Phase 3
    • Cilofexor, firsocostat, selonsertib combination3

      NASH

      Phase 1
      Phase 2
      Phase 3
    • Selonsertib ASK1 inhibitor (GS-4997)

      DKD

      Phase 1
      Phase 2
      Phase 3
    • GLPG-16901

      Systemic sclerosis

      Phase 1
      Phase 2
      Phase 3
    • GLPG-12052

      Idiopathic pulmonary fibrosis

      Phase 1
      Phase 2
      Phase 3

    1 Optioned parter program.

    2 Optionable partner program.

    3Cilofexor FXR agonist, firsocostat ACC inh., selonsertib ASK1 inh. Combination.

    Oncology

    • KTE-X19

      r/r MCL

      Phase 1
      Phase 2
      Phase 3
    • Axi-cel

      2L DLBCL

      Phase 1
      Phase 2
      Phase 3
    • Axi-cel

      Indolent NHL

      Phase 1
      Phase 2
      Phase 3
    • Axi-cel

      1L DLBCL

      Phase 1
      Phase 2
      Phase 3
    • Axi-cel

      3L DLBCL (+rituximab or lenalidomide)

      Phase 1
      Phase 2
      Phase 3
    • KTE-X19

      Adult ALL

      Phase 1
      Phase 2
      Phase 3
    • KTE-X19

      Pediatric ALL

      Phase 1
      Phase 2
      Phase 3
    • KTE-X19

      CLL

      Phase 1
      Phase 2
      Phase 3
    • Axi-cel

      3L DLBCL (+utomilumab)

      Phase 1
      Phase 2
      Phase 3
    • KITE-718 (MAGE-A3/A6)

      Solid tumor

      Phase 1
      Phase 2
      Phase 3
    • KITE-439 (HPV-16 E7)

      Solid tumor

      Phase 1
      Phase 2
      Phase 3
    • Oral PD-L1 inhibitor (GS-4224)

      Solid tumor

      Phase 1
      Phase 2
      Phase 3
    • anti-CD73/TGF? TRAP (GS-1423)1

      Solid tumor

      Phase 1
      Phase 2
      Phase 3
    • Bi-specific mAb (AGEN1223)2,3,4

      Multiple

      Phase 1
      Phase 2
      Phase 3
    • Anti-CD137 mAb mAb (AGEN2373)3,4

      Multiple

      Phase 1
      Phase 2
      Phase 3
    • Anti-CD47 (magrolimab)

      MDS

      Phase 1
      Phase 2
      Phase 3
    • Anti-CD47 (magrolimab)

      AML

      Phase 1
      Phase 2
      Phase 3
    • Anti-CD47 (magrolimab)

      NHL

      Phase 1
      Phase 2
      Phase 3
    • Anti-CD47 (magrolimab)

      Exploring solid tumor options

      Phase 1
      Phase 2
      Phase 3

    1 TME conditioning anti-CD73/TGF? TRAP bifunctional fusion protein (GS-1423).

    2 Bi-specific mAb targeting immunosuppressive regulatory T cells (AGEN1223).

    3 Exclusive option to license right from Agenus upon proof of concept data.

    4 Optionable partner program. ALL - Acute lymphocytic leukemia. CLL - Chronic lymphocytic leukemia. DLBCL - Diffuse large B-cell lymphoma. iNHL - Indolent non-Hodgkin lymphoma. MCL - Mantle cell lymphoma. r/r - relapsed refractory. iNHL - Indolent non-Hodgkin lymphoma.

    在线aⅴ自拍在线偷拍视频